TherapeuticsMD, Inc. operates as a pharmaceutical company. The company is headquartered in Boca Raton, Florida and currently employs 1 full-time employee. The company went IPO on 2001-01-31. The company receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) is a pharmaceutical product for the treatment of moderate-to-severe dyspareunia. BIJUVA is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA is a one-year, ring-shaped contraceptive vaginal system (CVS).
How did TXMD's recent EPS compare to expectations?
The most recent EPS for TherapeuticsMD Inc is $, expectations of $.
How did TherapeuticsMD Inc TXMD's revenue perform in the last quarter?
TherapeuticsMD Inc revenue for the last quarter is $
What is the revenue estimate for TherapeuticsMD Inc?
According to of Wall street analyst, the revenue estimate of TherapeuticsMD Inc range from $ to $
What's the earning quality score for TherapeuticsMD Inc?
TherapeuticsMD Inc has a earning quality score of B+/52.1198. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does TherapeuticsMD Inc report earnings?
TherapeuticsMD Inc next earnings report is expected in 2026-06-23
What are TherapeuticsMD Inc's expected earnings?
TherapeuticsMD Inc expected earnings is $, according to wall-street analysts.
Did TherapeuticsMD Inc beat earnings expectations?
TherapeuticsMD Inc recent earnings of $ expectations.